© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Skin Cancers
FDA Approves Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
June 24, 2020
Pembrolizumab received FDA approval for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by either surgery or radiation.
Fast Track Designation Granted to Seviprotimut-L Vaccine for Adjuvant Use in Stage IIB/IIC Melanoma
June 23, 2020
With a Fast Track designation, the development of seviprotimut-L will be facilitated and expeditiously reviewed by the FDA to address an unmet medical need for patients with stage IIB and IIIC melanoma,
Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC
May 31, 2020
“The data demonstrated deepening clinical responses with cemiplimab over time. Furthermore, duration of response and overall survival [OS] are considerably longer with cemiplimab than what has previously been recorded with other agents.”
Early Trials in Melanoma Show Better Response After 1 Year
May 12, 2020
Richard D. Carvajal, MD, discusses 2 therapies in clinical trials registering patients with melanoma.
Cemiplimab Induces Significant Responses in Second-line Basal Cell Carcinoma
May 05, 2020
"...These important new results further demonstrate Libtayo’s potential in patients with difficult-to-treat, non-melanoma skin cancers."
Engineered Cellular Therapies Enter Treatment Landscape of Melanoma
May 04, 2020
In an interview with Targeted Oncology, Bruce L. Levine, PhD, discussed hot topics in the treatment landscape of melanoma, including the development of chimeric antigen receptor T and NK cells.
Combination Regimens Inspire Hope for the Treatment of Melanoma
May 04, 2020
In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.
Positive Treatment Response Reinforced With SGX301 in Cutaneous T-Cell Lymphoma
April 30, 2020
"As anticipated, the data continues to become more compelling with extended SGX301 treatment."
ILLUMINATE-204 Update: Promising Results Reported With Tilsotolimod Plus Ipilimumab in Advanced Melanoma
April 21, 2020
"The clinical benefit suggested for these anti-PD-1 refractory melanoma patients with limited treatment options includes stabilization of disease and even responses, which is creating hope that this combination might be of benefit to patients in the PD-1 refractory setting."
Evaluating Prognosis of Patients With Ocular Melanoma
April 17, 2020
Ragini Kudchadkar, MD, discusses the overall prognosis of patients with ocular melanoma.